

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Insulin Glargine Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-
stance/Mixture : Pharmaceutical

Recommended restrictions
on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
Kilsheelan
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Skin irritation, Category 2	H315: Causes skin irritation.
Serious eye damage, Category 1	H318: Causes serious eye damage.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H315 Causes skin irritation.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

H318 Causes serious eye damage.
H373 May cause damage to organs through prolonged or repeated exposure.

Precautionary statements :

Prevention:

P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P280 Wear protective gloves/ eye protection/ face protection.

Response:

P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.
P314 Get medical advice/ attention if you feel unwell.
P332 + P313 If skin irritation occurs: Get medical advice/ attention.

Hazardous components which must be listed on the label:

Insulin Glargine
m-Cresol

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Insulin Glargine	160337-95-1	STOT RE 2; H373 (Blood, Nervous system)	>= 90 - <= 100
m-Cresol	108-39-4	Acute Tox. 3; H301	>= 3 - < 5

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

	203-577-9 604-004-00-9	Acute Tox. 3; H311 Skin Corr. 1B; H314 Eye Dam. 1; H318 Aquatic Chronic 3; H412 EUH071 Acute toxicity estimate Acute oral toxicity: 121 mg/kg Acute dermal toxicity: 301 mg/kg
--	---------------------------	--

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

- | | |
|----------------------------|--|
| General advice | : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : If inhaled, remove to fresh air.
Get medical attention if symptoms occur. |
| In case of skin contact | : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention immediately. |
| If swallowed | : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water. |

4.2 Most important symptoms and effects, both acute and delayed

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

Risks : Causes skin irritation.
Causes serious eye damage.
May cause damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	: Use only with adequate ventilation.
Advice on safe handling	: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version 5.0 Revision Date: 14.04.2025 SDS Number: 45342-00030 Date of last issue: 28.09.2024
Date of first issue: 07.01.2015

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Keep tightly closed.
Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:
Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Dust 5 mg/m³
Value type (Form of exposure): TWA (respirable dust)
Basis: FOR-2011-12-06-1358

10 mg/m³
Value type (Form of exposure): TWA (total dust)
Basis: FOR-2011-12-06-1358

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Insulin Glargine	160337-95-1	TWA	3 µg/m ³ (OEB 4)	Internal
m-Cresol	108-39-4	TWA	20 mg/m ³	FOR-2011-12-06-1358
Further information: Chemicals that can be absorbed through the skin.				

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
m-Cresol	Workers	Inhalation	Long-term systemic effects	3,5 mg/m ³
	Workers	Inhalation	Acute systemic effects	343 mg/m ³
	Workers	Skin contact	Long-term systemic effects	0,5 mg/kg bw/day
	Workers	Skin contact	Acute systemic effects	1,47 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	0,75 mg/m ³
	Consumers	Inhalation	Acute systemic effects	222 mg/m ³
	Consumers	Skin contact	Long-term systemic effects	0,25 mg/kg bw/day
	Consumers	Skin contact	Acute systemic ef-	0,74 mg/kg

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version 5.0 Revision Date: 14.04.2025 SDS Number: 45342-00030 Date of last issue: 28.09.2024
Date of first issue: 07.01.2015

			fects	bw/day
	Consumers	Ingestion	Long-term systemic effects	0,25 mg/kg bw/day
	Consumers	Ingestion	Acute systemic effects	0,74 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
m-Cresol	Fresh water	0,1 mg/l
	Marine water	0,01 mg/l
	Intermittent use/release	0,076 mg/l
	Sewage treatment plant	1,14 mg/l
	Fresh water sediment	0,71 mg/kg
	Marine sediment	0,071 mg/kg
	Soil	0,0831 mg/kg

8.2 Exposure controls

Engineering measures

Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Eye/face protection : Wear the following personal protective equipment:
Chemical resistant goggles must be worn.
If splashes are likely to occur, wear:
Face-shield
Equipment should conform to NS EN 166

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter should conform to NS EN 14387

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

II Filter type : Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	Crystalline powder
Colour	:	white
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
pH	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Vapour pressure	:	No data available
Density	:	No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

Relative vapour density : No data available

Particle characteristics
Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

|| Not classified based on available information.

Product:

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Components:

Insulin Glargine:

Acute oral toxicity : Remarks: No data available

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

m-Cresol:

Acute oral toxicity : LD50 (Rat): 121 mg/kg
Remarks: Based on data from similar materials

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

Acute dermal toxicity : LD50 (Rabbit): 301 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Causes skin irritation.

Components:

Insulin Glargine:

Remarks : No data available

m-Cresol:

Species : Rabbit

Result : Corrosive after 3 minutes to 1 hour of exposure

Serious eye damage/eye irritation

Causes serious eye damage.

Components:

Insulin Glargine:

Remarks : No data available

m-Cresol:

Species : Rabbit

Result : Irreversible effects on the eye

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

Respiratory or skin sensitisation

Skin sensitisation

|| Not classified based on available information.

Respiratory sensitisation

|| Not classified based on available information.

Components:

Insulin Glargine:

|| Remarks : No data available

Germ cell mutagenicity

|| Not classified based on available information.

Components:

Insulin Glargine:

|| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Result: negative
Remarks: Based on data from similar materials

m-Cresol:

|| Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow
cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Ingestion
Method: OECD Test Guideline 475
Result: negative

Carcinogenicity

|| Not classified based on available information.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

Components:

Insulin Glargine:

Species	: Rat
Exposure time	: 2 Years
NOAEL	: 0,455 mg/kg body weight
Result	: negative

Species	: Mouse
Exposure time	: 2 Years
NOAEL	: 0,455 mg/kg body weight
Result	: negative

m-Cresol:

Species	: Mouse, males
Application Route	: Ingestion
Exposure time	: 105 weeks
Result	: equivocal
Remarks	: Based on data from similar materials

Species	: Mouse, female
Application Route	: Ingestion
Exposure time	: 106 - 107 weeks
Result	: positive
Remarks	: Based on data from similar materials

Carcinogenicity - Assessment	: Weight of evidence does not support classification as a carcinogen
------------------------------	--

Reproductive toxicity

Not classified based on available information.

Components:

Insulin Glargine:

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Subcutaneous Fertility: NOAEL: 0,36 mg/kg body weight Result: No effects on fertility Test Type: Fertility/early embryonic development Species: Rabbit Application Route: Subcutaneous Fertility: NOAEL: 0,072 mg/kg body weight Result: No effects on fertility
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Subcutaneous Developmental Toxicity: NOAEL: 0,36 mg/kg body weight Result: No effects on foetal development

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

Species: Rabbit
Application Route: Subcutaneous
Developmental Toxicity: LOAEL: 0,072 mg/kg body weight
Result: Fetotoxicity
Remarks: The mechanism or mode of action may not be relevant in humans.

m-Cresol:

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal development	: Test Type: Prenatal development toxicity study (teratogenicity) Species: Rat Application Route: Ingestion Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

Insulin Glargine:

Exposure routes	: Ingestion
Target Organs	: Blood, Nervous system
Assessment	: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Insulin Glargine:

Species	: Rat
NOAEL	: 0,5 mg/kg
LOAEL	: 1,5 mg/kg
Application Route	: Subcutaneous
Exposure time	: 30 d
Target Organs	: Blood, Nervous system

m-Cresol:

Species	: Rat
NOAEL	: 150 mg/kg
Application Route	: Ingestion
Exposure time	: 13 Weeks
Method	: OECD Test Guideline 408

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

Aspiration toxicity

|| Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

|| Not classified based on available information.

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Insulin Glargine:

|| Inhalation : Target Organs: Blood
Symptoms: Hypoglycemia, Headache, Sweating, Tremors, Nausea

SECTION 12: Ecological information

12.1 Toxicity

Components:

m-Cresol:

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): 8,6 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia pulex (Water flea)): > 99,5 mg/l Exposure time: 48 h
Toxicity to fish (Chronic toxicity)	: NOEC: 1,35 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC: 1 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Remarks: Based on data from similar materials

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

12.2 Persistence and degradability

Components:

m-Cresol:

Biodegradability	:	Result: Readily biodegradable. Biodegradation: 90 % Exposure time: 28 d Method: OECD Test Guideline 301D
------------------	---	---

12.3 Bioaccumulative potential

Components:

m-Cresol:

Bioaccumulation	:	Species: Leuciscus idus (Golden orfe) Bioconcentration factor (BCF): 17 - 20
Partition coefficient: n-octanol/water	:	log Pow: 1,96

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment	:	This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
------------	---	--

12.6 Endocrine disrupting properties

Product:

Assessment	:	The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
------------	---	---

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in
---------	---	---

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

Contaminated packaging : discussion with the waste disposal authorities.
Do not dispose of waste into sewer.
Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

14.2 UN proper shipping name

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

14.4 Packing group

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA (Cargo)	: Not regulated as a dangerous good
IATA (Passenger)	: Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered: Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Regulation (EU) No 2024/590 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.
Not applicable

Other regulations:

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H301 : Toxic if swallowed.
H311 : Toxic in contact with skin.
H314 : Causes severe skin burns and eye damage.
H318 : Causes serious eye damage.
H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.
H412 : Harmful to aquatic life with long lasting effects.
EUH071 : Corrosive to the respiratory tract.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Aquatic Chronic : Long-term (chronic) aquatic hazard
Eye Dam. : Serious eye damage
Skin Corr. : Skin corrosion
STOT RE : Specific target organ toxicity - repeated exposure
FOR-2011-12-06-1358 : Norway. Occupational Exposure limits
FOR-2011-12-06-1358 / TWA : Long term exposure limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure-Activity Relationship

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.0	14.04.2025	45342-00030	Date of first issue: 07.01.2015

tative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Skin Irrit. 2	H315
Eye Dam. 1	H318
STOT RE 2	H373

Classification procedure:

Calculation method
Calculation method
Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN